Central obesity as a clinical marker of adiposopathy; increased visceral adiposity as a surrogate marker for global fat dysfunction
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: Subcutaneous adipose tissue (SAT) is often described as 'protective'. Visceral adipose tissue (VAT) is often described as 'pathologic'. However, both SAT and VAT have protective and pathologic potential, with interdependent biologic functions. RECENT FINDINGS: Most of the body's (excess) energy is stored as fat in SAT. If during positive caloric balance, SAT does not undergo adequate adipogenesis, then excess energy may result in adipocyte hypertrophy, leading to hypoxia, immunopathies, and endocrinopathies. Energy overflow may promote accumulation of pericardial fat, perivascular fat, and myocardial fat, which may directly contribute to atherosclerotic cardiovascular disease (CVD). Lipotoxic free fatty acid delivery to nonadipose body organs (e.g. liver, muscle, and pancreas) may indirectly contribute to CVD by promoting the most common metabolic disorders encountered in clinical practice (e.g. high blood sugars, high blood pressure, and dyslipidaemia), all major CVD risk factors. Finally, SAT energy overflow may increase VAT accumulation, which is also associated with increased risk of metabolic diseases and CVD. SUMMARY: Increased VAT is a surrogate marker for SAT dysfunction which increases waist circumference, reflecting a shared pathologic process leading to the pathogenic fat accumulation of other fat depots and fatty infiltration of nonadipose body organs. Central obesity is a clinical marker for adiposopathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fox, C. S., Massaro, J. M., Hoffmann, U., Pou, K. M., Maurovich-Horvat, P., Liu, C.-Y., Vasan, R. S., Murabito, J. M., Meigs, J. B., Cupples, L. A., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.675355 · Cited by 2,882
Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity
Fabbrini, E., Magkos, F., Mohammed, B. S., Pietka, T., Abumrad, N. A., Patterson, B. W., Okunade, A., & Klein, S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904944106 · Cited by 972
Bays, H., Mandarino, L., & DeFronzo, R. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030723 · Cited by 664
Self-citationObesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association
Bays, H. E., Toth, P. P., Kris-Etherton, P. M., Abate, N., Aronne, L. J., Brown, W. V., Gonzalez-Campoy, J. M., Jones, S. R., Kumar, R., La Forge, R., et al. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.04.001 · Cited by 521
Self-citationBays, H. E. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.02.038 · Cited by 431 · cited 17×
“It helps explain why the best surgical interventions to improve adiposopathic metabolic abnormalities are those that reduce total body fat, as often achieved with bariatric surgery, which represents among the most effective treatment for metabolic disease, and CVD risk reduction in individuals who are overweight or ob…”
BackgroundInfluentialSelf-citationPerivascular adipose tissue: More than just structural support
Szasz, T., & Webb, R. C. (2012) · Clinical Science · doi:10.1042/cs20110151 · Cited by 265
The relationship of omental and subcutaneous adipocyte size to metabolic disease in severe obesity
O'Connell, J., Lynch, L., Cawood, T. J., Kwasnik, A., Nolan, N., Geoghegan, J., McCormick, A., O'Farrelly, C., & O'Shea, D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009997 · Cited by 211
The case of visceral fat: argument for the defense
Klein, S. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422028 · Cited by 206
Bays, H. E. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.08.029 · Cited by 73
Self-citation
Cited by
Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over
Ryan, D. H., & Yockey, S. R. (2017) · Current Obesity Reports · doi:10.1007/s13679-017-0262-y · Cited by 831
Why primary obesity is a disease?
De Lorenzo, A., Gratteri, S., Gualtieri, P., Cammarano, A., Bertucci, P., & Di Renzo, L. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1919-y · Cited by 370
Lopez-Jimenez, F., Almahmeed, W., Bays, H., Cuevas, A., Di Angelantonio, E., le Roux, C. W., Sattar, N., Sun, M. C., Wittert, G., Pinto, F. J., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac187 · Cited by 362
“Positive energy balance results in adipocyte hypertrophy and ectopic fat accumulation that leads to organelle dysfunction (e.g. 52 Under conditions, the most common CVD risk factors”
InfluentialSelf-citationObesity and cancer: the role of adipose tissue and adipo-cytokines-induced chronic inflammation
Divella, R., De Luca, R., Abbate, I., Naglieri, E., & Daniele, A. (2016) · Journal of Cancer · doi:10.7150/jca.16884 · Cited by 335
Ten things to know about ten cardiovascular disease risk factors
Bays, H. E., Taub, P. R., Epstein, E., Michos, E. D., Ferraro, R. A., Bailey, A. L., Kelli, H. M., Ferdinand, K. C., Echols, M. R., Weintraub, H., et al. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100149 · Cited by 274
Self-citation
Metadata
- Authors
- Bays, H.
- Venue
- Current Opinion in Endocrinology, Diabetes & Obesity
- Published
- 2014-10
- Volume
- 21
- Issue
- 5
- Pages
- 345-351
- ISSN
- 1752-296X (ISSN-L)
- OpenAlex
- W2013047979
- Cited by
- 142
- References
- 9
- FWCI
- 9.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Central obesity as a clinical marker of adiposopathy; increased visceral adiposity as a surrogate marker for global fat dysfunction. https://app.cochat.ai/papers/10.1097/med.0000000000000093
- The paper
- Bays, H. (2014). Central obesity as a clinical marker of adiposopathy; increased visceral adiposity as a surrogate marker for global fat dysfunction. Current Opinion in Endocrinology, Diabetes & Obesity. https://doi.org/10.1097/med.0000000000000093
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.